Phase II Study of the Triple Combination Chemotherapy of SOXIRI (S‐1/Oxaliplatin/Irinotecan) in Patients with Unresectable Pancreatic Ductal Adenocarcinoma

LESSONS LEARNED. The triple combination chemotherapy of SOXIRI (S‐1/oxaliplatin/irinotecan) in patients with unresectable pancreatic ductal adenocarcinoma was an effective treatment that appeared to be better tolerated than the widely used FOLFIRINOX regimen. SOXIRI regimen may provide an alternativ...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncologist
Autors principals: Akahori, Takahiro, Sho, Masayuki, Yanagimoto, Hiroaki, Satoi, Sohei, Nagai, Minako, Nishiwada, Satoshi, Nakagawa, Kenji, Nakamura, Kota, Yamamoto, Tomohisa, Hirooka, Satoshi, Yamaki, So, Ikeda, Naoya
Format: Artigo
Idioma:Inglês
Publicat: John Wiley & Sons, Inc. 2019
Matèries:
Clinical Trial Results
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6656520/
https://ncbi.nlm.nih.gov/pubmed/30679316
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0900
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars